Boomi Launches New Veeva Vault Connector to Simplify Application Integration in the Life Sciences Industry
Boomi connector streamlines integration of third-party applications with Veeva Vault, uniting content and data for seamless, end-to-end business processes
Boomi™, the intelligent integration and automation leader, today announced the launch of a new specialized connector designed to streamline integration between third-party systems and the Veeva Vault platform. This expands Boomi’s collaboration with Veeva Systems, a leading global provider of cloud-based software solutions for the life sciences industry, to bring together content and data for mutual customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024317066/en/
Boomi Launches New Veeva Vault Connector to Simplify Application Integration in the Life Sciences Industry (Graphic: Business Wire)
As life sciences companies increasingly modernize operations with advanced solutions, the demand for seamless connectivity for their Veeva applications – from commercial to R&D, and quality – with complementary business applications continues to grow. The Boomi connector for Veeva Vault simplifies this process by leveraging the latest Vault APIs for comprehensive data access. By enabling users to avoid manual, time-consuming, and error-prone coding projects, the connector streamlines the integration process and drives efficiency gains.
"The integration of the Veeva Vault Platform with other applications and data sources is critical for life sciences companies looking to modernize their operations," said Ed Macosky, Chief Product and Technology Officer at Boomi. "Boomi is committed to being the go-to integration platform for Veeva customers, simplifying the integration process while meeting the unique requirements of the life sciences and pharmaceutical industries.”
Key Advantages of the Boomi Connector for Veeva Vault:
- Streamlined Connectivity: The Boomi connector for Veeva Vault simplifies the integration process, leveraging the latest Vault APIs for comprehensive data access. This alleviates the burden of manual coding while enhancing the user experience.
- Low-Code Development Environment: The Boomi Enterprise Platform allows researchers and business stakeholders to quickly create and deploy integrations, automating their processes without the need for extensive coding expertise.
- Flexible and Secure: With options for cloud, on-premises, and hybrid deployments, Veeva customers can configure their integration services to meet stringent regulatory compliance standards, including HIPAA.
- Automation for Accelerated Business Processes: Once integrated, Veeva customers can leverage the Boomi Enterprise Platform to automate workflows using Veeva Vault data, enhancing operational efficiency and driving faster decision-making.
“Veeva Vault is the foundation for drug development and commercialization in life sciences. Seamless integration of Vault applications, including Vault CRM, with other third-party systems is essential for operational efficiency,” said Jared Katz, Senior Director, Veeva Development Cloud Strategy. “With its low-code platform and connector to Vault, Boomi helps to streamline and simplify the integration process.”
Learn more about using the Boomi Enterprise Platform to integrate with Veeva Vault here. Get started with the Veeva Vault Connector here.
Additional Resources
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With a customer base exceeding 20,000 companies globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024317066/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000® Index28.6.2025 01:30:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 22:44:00 CEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
Andersen Consulting udvider sine kompetencer inden for forretningstransformation med tilføjelsen af The Clearing27.6.2025 16:48:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin platform med samarbejdsfirmaet The Clearing, som er en managementkonsulentvirksomhed med speciale i organisatorisk omstilling og lederudvikling. The Clearing blev stiftet i 2009 og rådgiver kunder om komplekse udfordringer ved at afstemme ledelse, strategi, kultur og drift. Firmaet arbejder med føderale agenturer, virksomheder og nonprofitorganisationer med henblik på at skabe målbare forandringer på tværs af forskellige interessenter til gavn for en leders vision og strategi. Med dyb erfaring inden for flere sektorer, herunder national sikkerhed, sundhedspleje og finansielle tjenester, leder The Clearings unikke blanding af talent med ekspertise inden for organisationsudvikling, dataanalyse og visuel rådgivning forretningstransformationer i stor skala og arbejder sammen med kunder og eksperter for at sikre, at rådgivning omsættes til implementering. "Vi leverer transformative resultater, der ikke kun er i overensstemmelse med strategiske mål, men også
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 16:00:00 CEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 14:00:00 CEST | Press release
New instrument automates tissue processing for researchers in cancer, immunology and other science fields To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom